Patient portrayal.
Patient portrayal.
In a clinical trial, SHINGRIX has been shown to be over 90% effective at preventing shingles across 7344 individuals 50 years and older who received both doses of the vaccine.1,2‡
SHINGRIX helps to offer sustained protection against shingles up to year 11.2-5†
‡Data from ZOE-50 phase 3 trial. Vaccine efficacy against shingles: 97.2% (95% CI 93.7, 99.0). Shingles cases in the SHINGRIX group: 6 out of 7,344. Median follow-up period of 3.1 years.1
†Separate clinical studies were conducted with immunocompromised population.6-8
SHINGRIX is designed to help overcome age-related decline in immunity.1,2,9,10
Your immune system declines as you age, and that puts you at an increased risk of shingles.9,11,12
SHINGRIX has been developed to help the immune system defend against shingles, even in the elderly population.1-5,10,11
SHINGRIX is a 2 dose vaccine – an initial dose is given followed by a second dose 2 to 6 months later. If you have a weakened immune system there may be a shorter period of time between doses.1
To maximise the protection offered by SHINGRIX, it is important that you get both doses.1,13
SHINGRIX is a 2-dose vaccine series (0.5 mL each) administered as an injection into a muscle, usually in the upper arm. It is important to complete the 2‑dose series to help prevent shingles.1
After receiving SHINGRIX, you may experience: pain, redness and swelling at the injection site, tiredness, headache, chills, fever, nausea, vomiting, diarrhoea, stomach pain and joint pain.1,14
As with any vaccine, vaccination with SHINGRIX can have side effects.14
SHINGRIX has benefits and risks – ask your doctor if SHINGRIX is right for you.
Side effects of SHINGRIX include:1,14
Pain, redness and swelling at the injection site, chills, tiredness, fever, headache, nausea, vomiting, diarrhoea, stomach pain.
In a pooled analysis of two large SHINGRIX studies, local and general symptoms in the group that received SHINGRIX were mostly mild to moderate in intensity and transient, with a median duration of 3 days or less for local and 2 days or less for general symptoms.7
If you are at increased risk of shingles, you are more likely to experience side effects such as pain at the injection site, fatigue, muscle pain, headache, shivering and fever if you are between the ages of 18 to 49 years, compared to if you are 50 years and older.14
SHINGRIX is fully funded for individuals at the age of 65 years old.13,15 It is not funded but recommended from the age of 50 years, including those aged 66 years and older.13
Please speak to your healthcare professional about expected costs.
SHINGRIX is also funded for individuals 18 years and over at higher risk of shingles with any of the following:13,15
Costs will apply if SHINGRIX is not funded.15
SHINGRIX helps provide over 90%# protection against shingles for individuals aged 50 years and above.1,2
As with all vaccines, SHINGRIX may not fully protect all people who are vaccinated. SHINGRIX has benefits and risks.1,14
#Data from ZOE-50 phase 3 trial. Vaccine efficacy against shingles: 97.2% (95% CI 93.7, 99.0). Shingles cases in the SHINGRIX group: 6 out of 7,344. Median follow-up period of 3.1 years.1
Don’t let shingles make you miss everyday and not so everyday events.16,17,19
ABOUT 1 IN 3 PEOPLE WILL GET SHINGLES IN THEIR LIFETIME, AND THE RISK INCREASES WITH AGE.13,18,19*
Shingles can have a negative effect on your quality of life and impact daily activities; such as sleep, work, and mood.17,19 In most cases, immunisation helps reduce your risk of shingles.2,14
*US data, may not be representative of the New Zealand population.19
Ask your pharmacist, doctor or nurse if SHINGRIX is right for you.
